Trial intelligence / Profile preview

Spleen aminopeptide oral lyophilized powder plus platinum chemotherapy in advanced breast cancer

ChiCTR-IPR-17013733Phase 4Recruiting

Sponsor
Beijing Friendship Hospital
Start
Dec 2017
Modality
Peptides
Countries
1
01

Overview

Phase 4, randomised, double-blind trial of spleen polypeptide in breast cancer (2 arms), sponsored by Beijing Friendship Hospital. Primary endpoint: Quality of life improvement on day 42. Started Dec 2017; status: recruiting.

02

Drugs

spleen polypeptide
03

Conditions

breast cancer

Beyond the preview

Go deeper on ChiCTR-IPR-17013733.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR-IPR-17013733.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call